Clinical Trial

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and 68Ga-PSMA are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET/CT scan. It is not yet known whether giving fluciclovine F18 or 68Ga-PSMA may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-08-08
minor Completion pushed: 2025-12-31 -> 2030-05-19 2026-08-08
Trial Details
NCT Number NCT03762759
Lead Sponsor Emory University
Collaborators: Telix Pharmaceuticals (Innovations) Pty Limited, National Cancer Institute (NCI), National Institutes of Health (NIH)
Conditions Prostate Adenocarcinoma
Enrollment 140 participants
Start Date 2019-05-10
Primary Completion 2025-05-19 (estimated)
Study Completion 2030-05-19 (estimated)
Updated on ClinicalTrials.gov 2026-08-07